Insight Molecular Diagnostics Inc. Travel and Entertainment Expense
Insight Molecular Diagnostics Inc. (IMDX) reported Travel and Entertainment Expense of $288.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:TravelAndEntertainmentExpense · last filed 2026-08-10
- Insight Molecular Diagnostics Inc. travel and entertainment expense for the quarter ending 2026-06-30 was $288.00K, a 11.20% increase year-over-year.
- Insight Molecular Diagnostics Inc. travel and entertainment expense for the quarter ending 2026-03-31 was $286.00K, a 46.67% increase year-over-year.
- Insight Molecular Diagnostics Inc. travel and entertainment expense for the quarter ending 2025-12-31 was $210.00K, a 40.00% increase year-over-year.
- Insight Molecular Diagnostics Inc. travel and entertainment expense for the quarter ending 2025-09-30 was $185.00K, a 2.12% decline year-over-year.
- Insight Molecular Diagnostics Inc. travel and entertainment expense for fiscal 2025 was $849.00K, a 45.13% increase from fiscal 2024.
- Insight Molecular Diagnostics Inc. travel and entertainment expense for fiscal 2024 was $585.00K.
| Period end | Travel and Entertainment Expense 3 month | Travel and Entertainment Expense 6 month | Travel and Entertainment Expense 9 month | Travel and Entertainment Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $288.00K 10-Q · filed 2026-08-10 | $574.00K 10-Q · filed 2026-08-10 | $784.00K derived: sum of 3 quarters · filed 2026-08-10 | $969.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $286.00K 10-Q · filed 2026-05-13 | $496.00K derived: sum of 2 quarters · filed 2026-05-13 | $681.00K derived: sum of 3 quarters · filed 2026-05-13 | $940.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $395.00K derived: sum of 2 quarters · filed 2026-03-26 | $654.00K derived: sum of 3 quarters · filed 2026-08-10 | $849.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $185.00K 10-Q · filed 2025-11-10 | $444.00K derived: sum of 2 quarters · filed 2026-08-10 | $639.00K 10-Q · filed 2025-11-10 | $789.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $259.00K 10-Q · filed 2026-08-10 | $454.00K 10-Q · filed 2026-08-10 | $604.00K derived: sum of 3 quarters · filed 2026-08-10 | $793.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $195.00K 10-Q · filed 2026-05-13 | $345.00K derived: sum of 2 quarters · filed 2026-05-13 | $534.00K derived: sum of 3 quarters · filed 2026-05-13 | $709.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $339.00K derived: sum of 2 quarters · filed 2026-03-26 | $514.00K derived: sum of 3 quarters · filed 2026-03-26 | $585.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $189.00K 10-Q · filed 2025-11-10 | $364.00K derived: sum of 2 quarters · filed 2025-11-10 | $435.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $175.00K 10-Q · filed 2025-08-11 | $246.00K 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |